Hypermagnesemia predicts mortality in elderly with congestive heart disease: Relationship with laxative and antacid use

Graziamaria Corbi, Domenico Acanfora, Gian Luca Iannuzzi, Giancarlo Longobardi, Francesco Cacciatore, Giuseppe Furgi, Amelia Filippelli, Giuseppe Rengo, Dario Leosco, Nicola Ferrara

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The aim of this study was to evaluate the role of magnesium levels on 3-year survival in the elderly with congestive heart failure (CHF) admitted to the Rehabilitative Cardiology Unit of S. Maugeri Foundation Scientific Institute of Telese/Campoli. All elderly patients ≥65 years old with a diagnosis of CHF underwent clinical and instrumental examination, and their demographics, co-morbidity, and in-hospital and 3-year mortality rates were recorded. Hypomagnesemia was found in 4.8%, normomagnesemia in 67.5%, and hypermagnesemia in 27.8% of subjects. The hypomagnesemic group was excluded for numerical exiguity; the analysis was performed on a total of 199 elderly patients. Hypermagnesemia was found in 29.1% and normomagnesemia in 70.9%. At the univariate analysis no differences were found in hypermagnesemia in respect to normomagnesemia group, except for slightly higher levels of creatininemia (1.35 ± 0.61 vs. 1.13 ± 0.55 mg/dL, respectively; p <0.02), greater disability (lost ADL, 2.69 ± 1.57 vs. 2.15 ± 1.56, respectively; p <0.05), more mortality for CHF (32.6 vs. 48.3%; p <0.05), and higher antacid and laxative use (82.7 vs. 24.8%, respectively; p <0.0001). Patients with higher magnesium showed less probability to survive at a 3-year follow-up than did patients with lower levels (17.32 ± 15.93 vs. 22.46 ± 16.16 months; p <0.05), and this finding remained significant in the multivariate analysis after adjusting for some confounders. Finally hypermagnesemia should also be considered in the absence of pre-existing renal failure clinical evidence because of its negative prognostic value, especially in elderly patients with CHF. The shown relationship between hypermagnesemia and laxative/antacid use should induce physicians to pay more attention to abuse of these drugs.

Original languageEnglish
Pages (from-to)129-138
Number of pages10
JournalRejuvenation Research
Volume11
Issue number1
DOIs
Publication statusPublished - Feb 1 2008

Fingerprint

Antacids
Laxatives
Heart Diseases
Heart Failure
Mortality
Magnesium
Activities of Daily Living
Cardiology
Substance-Related Disorders
Renal Insufficiency
Multivariate Analysis
Demography
Morbidity
Physicians
Survival

ASJC Scopus subject areas

  • Ageing

Cite this

Hypermagnesemia predicts mortality in elderly with congestive heart disease : Relationship with laxative and antacid use. / Corbi, Graziamaria; Acanfora, Domenico; Iannuzzi, Gian Luca; Longobardi, Giancarlo; Cacciatore, Francesco; Furgi, Giuseppe; Filippelli, Amelia; Rengo, Giuseppe; Leosco, Dario; Ferrara, Nicola.

In: Rejuvenation Research, Vol. 11, No. 1, 01.02.2008, p. 129-138.

Research output: Contribution to journalArticle

Corbi, Graziamaria ; Acanfora, Domenico ; Iannuzzi, Gian Luca ; Longobardi, Giancarlo ; Cacciatore, Francesco ; Furgi, Giuseppe ; Filippelli, Amelia ; Rengo, Giuseppe ; Leosco, Dario ; Ferrara, Nicola. / Hypermagnesemia predicts mortality in elderly with congestive heart disease : Relationship with laxative and antacid use. In: Rejuvenation Research. 2008 ; Vol. 11, No. 1. pp. 129-138.
@article{3fc9012234c54f6bb15bae623916fc40,
title = "Hypermagnesemia predicts mortality in elderly with congestive heart disease: Relationship with laxative and antacid use",
abstract = "The aim of this study was to evaluate the role of magnesium levels on 3-year survival in the elderly with congestive heart failure (CHF) admitted to the Rehabilitative Cardiology Unit of S. Maugeri Foundation Scientific Institute of Telese/Campoli. All elderly patients ≥65 years old with a diagnosis of CHF underwent clinical and instrumental examination, and their demographics, co-morbidity, and in-hospital and 3-year mortality rates were recorded. Hypomagnesemia was found in 4.8{\%}, normomagnesemia in 67.5{\%}, and hypermagnesemia in 27.8{\%} of subjects. The hypomagnesemic group was excluded for numerical exiguity; the analysis was performed on a total of 199 elderly patients. Hypermagnesemia was found in 29.1{\%} and normomagnesemia in 70.9{\%}. At the univariate analysis no differences were found in hypermagnesemia in respect to normomagnesemia group, except for slightly higher levels of creatininemia (1.35 ± 0.61 vs. 1.13 ± 0.55 mg/dL, respectively; p <0.02), greater disability (lost ADL, 2.69 ± 1.57 vs. 2.15 ± 1.56, respectively; p <0.05), more mortality for CHF (32.6 vs. 48.3{\%}; p <0.05), and higher antacid and laxative use (82.7 vs. 24.8{\%}, respectively; p <0.0001). Patients with higher magnesium showed less probability to survive at a 3-year follow-up than did patients with lower levels (17.32 ± 15.93 vs. 22.46 ± 16.16 months; p <0.05), and this finding remained significant in the multivariate analysis after adjusting for some confounders. Finally hypermagnesemia should also be considered in the absence of pre-existing renal failure clinical evidence because of its negative prognostic value, especially in elderly patients with CHF. The shown relationship between hypermagnesemia and laxative/antacid use should induce physicians to pay more attention to abuse of these drugs.",
author = "Graziamaria Corbi and Domenico Acanfora and Iannuzzi, {Gian Luca} and Giancarlo Longobardi and Francesco Cacciatore and Giuseppe Furgi and Amelia Filippelli and Giuseppe Rengo and Dario Leosco and Nicola Ferrara",
year = "2008",
month = "2",
day = "1",
doi = "10.1089/rej.2007.0583",
language = "English",
volume = "11",
pages = "129--138",
journal = "Rejuvenation Research",
issn = "1549-1684",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Hypermagnesemia predicts mortality in elderly with congestive heart disease

T2 - Relationship with laxative and antacid use

AU - Corbi, Graziamaria

AU - Acanfora, Domenico

AU - Iannuzzi, Gian Luca

AU - Longobardi, Giancarlo

AU - Cacciatore, Francesco

AU - Furgi, Giuseppe

AU - Filippelli, Amelia

AU - Rengo, Giuseppe

AU - Leosco, Dario

AU - Ferrara, Nicola

PY - 2008/2/1

Y1 - 2008/2/1

N2 - The aim of this study was to evaluate the role of magnesium levels on 3-year survival in the elderly with congestive heart failure (CHF) admitted to the Rehabilitative Cardiology Unit of S. Maugeri Foundation Scientific Institute of Telese/Campoli. All elderly patients ≥65 years old with a diagnosis of CHF underwent clinical and instrumental examination, and their demographics, co-morbidity, and in-hospital and 3-year mortality rates were recorded. Hypomagnesemia was found in 4.8%, normomagnesemia in 67.5%, and hypermagnesemia in 27.8% of subjects. The hypomagnesemic group was excluded for numerical exiguity; the analysis was performed on a total of 199 elderly patients. Hypermagnesemia was found in 29.1% and normomagnesemia in 70.9%. At the univariate analysis no differences were found in hypermagnesemia in respect to normomagnesemia group, except for slightly higher levels of creatininemia (1.35 ± 0.61 vs. 1.13 ± 0.55 mg/dL, respectively; p <0.02), greater disability (lost ADL, 2.69 ± 1.57 vs. 2.15 ± 1.56, respectively; p <0.05), more mortality for CHF (32.6 vs. 48.3%; p <0.05), and higher antacid and laxative use (82.7 vs. 24.8%, respectively; p <0.0001). Patients with higher magnesium showed less probability to survive at a 3-year follow-up than did patients with lower levels (17.32 ± 15.93 vs. 22.46 ± 16.16 months; p <0.05), and this finding remained significant in the multivariate analysis after adjusting for some confounders. Finally hypermagnesemia should also be considered in the absence of pre-existing renal failure clinical evidence because of its negative prognostic value, especially in elderly patients with CHF. The shown relationship between hypermagnesemia and laxative/antacid use should induce physicians to pay more attention to abuse of these drugs.

AB - The aim of this study was to evaluate the role of magnesium levels on 3-year survival in the elderly with congestive heart failure (CHF) admitted to the Rehabilitative Cardiology Unit of S. Maugeri Foundation Scientific Institute of Telese/Campoli. All elderly patients ≥65 years old with a diagnosis of CHF underwent clinical and instrumental examination, and their demographics, co-morbidity, and in-hospital and 3-year mortality rates were recorded. Hypomagnesemia was found in 4.8%, normomagnesemia in 67.5%, and hypermagnesemia in 27.8% of subjects. The hypomagnesemic group was excluded for numerical exiguity; the analysis was performed on a total of 199 elderly patients. Hypermagnesemia was found in 29.1% and normomagnesemia in 70.9%. At the univariate analysis no differences were found in hypermagnesemia in respect to normomagnesemia group, except for slightly higher levels of creatininemia (1.35 ± 0.61 vs. 1.13 ± 0.55 mg/dL, respectively; p <0.02), greater disability (lost ADL, 2.69 ± 1.57 vs. 2.15 ± 1.56, respectively; p <0.05), more mortality for CHF (32.6 vs. 48.3%; p <0.05), and higher antacid and laxative use (82.7 vs. 24.8%, respectively; p <0.0001). Patients with higher magnesium showed less probability to survive at a 3-year follow-up than did patients with lower levels (17.32 ± 15.93 vs. 22.46 ± 16.16 months; p <0.05), and this finding remained significant in the multivariate analysis after adjusting for some confounders. Finally hypermagnesemia should also be considered in the absence of pre-existing renal failure clinical evidence because of its negative prognostic value, especially in elderly patients with CHF. The shown relationship between hypermagnesemia and laxative/antacid use should induce physicians to pay more attention to abuse of these drugs.

UR - http://www.scopus.com/inward/record.url?scp=39449126469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39449126469&partnerID=8YFLogxK

U2 - 10.1089/rej.2007.0583

DO - 10.1089/rej.2007.0583

M3 - Article

C2 - 18279030

AN - SCOPUS:39449126469

VL - 11

SP - 129

EP - 138

JO - Rejuvenation Research

JF - Rejuvenation Research

SN - 1549-1684

IS - 1

ER -